April 26, 2019 / 6:11 AM / a month ago

AstraZeneca first-quarter product sales beat estimates

April 26 (Reuters) - British drugmaker AstraZeneca Plc’s first-quarter product sales beat analysts’ expectations on Friday, benefiting from higher demand for its cancer medicines.

Product sales rose 14 percent at constant currency to $5.47 billion.

The company, fresh off an oncology deal with Japan’s Daiichi Sankyo Co Ltd, in February reported annual sales growth for the first time since 2009, turning the business around after a series of patent losses.

Analysts on average were expecting product sales of $5.29 billion, according to a company provided consensus of 19 analysts. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Bernard Orr)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below